GURUFOCUS.COM » STOCK LIST » Oceania » Australia » ASX » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Debt-to-Revenue
Switch to:

Vectus Biosystems (ASX:VBS) Debt-to-Revenue

: 0.00 (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Vectus Biosystems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems's annualized Revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Vectus Biosystems Debt-to-Revenue Historical Data

The historical data trend for Vectus Biosystems's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A - N/A -

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems Debt-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Debt-to-Revenue falls into.



Vectus Biosystems Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Vectus Biosystems's Debt-to-Revenue for the fiscal year that ended in Jun. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.946 + 0.07) / N/A
=N/A

Vectus Biosystems's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Vectus Biosystems Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines